Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering novel, small-molecule precision medicines. Their core approach involves leveraging the body's inherent mechanisms to precisely eliminate therapeutically relevant proteins. Among their key initiatives is an oral molecular glue degrader designed to target GSPT1, a specific translational termination factor and degron-containing protein, with the aim of treating Myc-driven cancers. The company's pipeline further includes programs for CDK2 in ovarian, uterine, and breast cancers, alongside NEK7 for addressing a spectrum of inflammatory conditions such as Crohn's disease, neurodegenerative ailments, diabetes, and liver disease. Moreover, VAV1 is being explored as a target for autoimmune disorders, and BCL11A, a protein holding significant therapeutic relevance, is under investigation for hemoglobinopathies. Founded in 2019, Monte Rosa Therapeutics, Inc. operates from its headquarters in Boston, Massachusetts.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Monte Rosa Therapeutics, Inc.
NASDAQ:GLUEHealthcare · Biotechnology
-1.01%$10.76
AH$10.76+0.00%vs close
Mkt Cap$917.97M
Float49.32M
O/S85.31M
Vol
$ Vol
RVOL
Inst Own-
SI41.9%
Earnings
Dilution
Financials Summary
Revenue$123.67M
Net Income-$38.63M
Total Assets$448.66M
Free Cash Flow-$27.5M
Debt & Equity
Debt 14%
Equity 86%
Total Debt$39.19M
Total Equity$233.06M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in GLUE's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$448.66M
Liabilities$215.6M
Accounts Receivable$4.6M
Accounts Payable$3.55M
Inventory$0
PP&E (Net)$50.37M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $123.67M | $75.62M | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | 63.5% | - | - | - | - | - | - |
| Cost of Revenue | $8.36M | $8.12M | $6.22M | $0 | $0 | $537K | $72K |
| Gross Profit | $115.32M | $67.5M | -$6.22M | $0 | $0 | -$537K | -$72K |
| Gross Margin | 93.2% | 89.3% | - | - | - | - | - |
| Research and Development | $141.5M | $121.56M | $105.05M | $85.06M | $57.16M | $23.47M | $7.35M |
| Selling, General, and Administrative | $36.38M | $35.17M | $32.04M | $27.32M | $15.73M | $4M | $644K |
| Other | -$8.36M | -$8.12M | $0 | $0 | $0 | $0 | $0 |
| Total Operating Expenses | $169.52M | $148.61M | $137.09M | $112.38M | $72.88M | $27.47M | $7.99M |
| Operating Income (EBIT) | -$54.21M | -$81.11M | -$143.31M | -$112.38M | -$72.88M | -$28.01M | -$7.99M |
| Operating Margin | -43.8% | -107.3% | - | - | - | - | - |
| Interest Expense | $0 | $0 | $0 | $3.76M | $0 | $0 | $1K |
| Interest Income | $12.94M | $10.57M | $9.33M | $3.76M | $46K | $9K | $12 |
| Other Income (Expense) | $14.48M | $10.98M | $8.3M | $3.88M | -$1.08M | -$7.87M | $254K |
| Income Before Tax (EBT) | -$39.72M | -$70.13M | -$135.01M | -$108.5M | -$73.96M | -$35.88M | -$7.74M |
| Income Tax Expense | -$1.1M | $2.57M | $338K | $0 | $0 | $0 | $0 |
| Net Income | -$38.63M | -$72.7M | -$135.35M | -$108.5M | -$73.96M | -$35.88M | -$8.02M |
| Net Income Margin | -31.2% | -96.1% | - | - | - | - | - |
| Supplementary Data | |||||||
| EPS | -0.59 | -0.98 | -2.63 | -2.30 | -1.59 | -0.82 | -0.18 |
| Diluted EPS | -0.59 | -0.98 | -2.63 | -2.30 | -1.59 | -0.82 | -0.18 |
| Weighted Average OS | 65.54M | 73.91M | 51.40M | 47.23M | 46.54M | 44.00M | 44.00M |
| EBITDA | -$31.37M | -$62.01M | -$128.79M | -$100.99M | -$71.83M | -$27.47M | -$7.67M |
| EBITDA Margin | -25.4% | -82.0% | - | - | - | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $129.88M | $224.25M | $128.1M | $54.91M | $346.07M | $41.7M | $6M |
| Short-Term Investments | $247.22M | $147.9M | $104.31M | $207.91M | $0 | $0 | $0 |
| Cash and Short-Term Investments | $377.1M | $372.15M | $232.41M | $262.83M | $346.07M | $41.7M | $6M |
| Accounts Receivable | $4.6M | $173K | $505K | $7.66M | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $11.48M | $5.12M | $3.29M | $5.4M | $0 | $100K | $3.25M |
| Total Current Assets | $393.19M | $377.44M | $236.21M | $275.89M | $348.67M | $43.59M | $9.76M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $50.37M | $56.31M | $62.61M | $61.91M | $12.32M | $4.62M | $1.33M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $5.34M | $1.16M | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $5.1M | $4.98M | $4.93M | $4.6M | $0 | $0 | $0 |
| Total Long-Term Assets | $55.47M | $61.29M | $67.54M | $66.5M | $17.66M | $5.79M | $1.33M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $448.66M | $438.73M | $303.75M | $342.39M | $366.33M | $49.38M | $11.09M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $3.55M | $17.21M | $11.15M | $7.86M | $6.56M | $7.07M | $3.19M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $750K |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $29.57M | $117.23M | $17.68M | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $11.58M | $11.57M | $9.26M | $10.64M | $840K | $21.08M | $0 |
| Total Current Liabilities | $64.21M | $156.95M | $46.59M | $25.57M | $16.64M | $29.27M | $4.29M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $34.79M | $0 | $0 | $0 | $0 | $67.76M | $0 |
| Long-Term Unearned Revenue | $111.33M | $16.15M | $32.32M | $0 | $0 | $1.07M | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $5.26M | $3.7M | $2.71M | $1.53M | $2.18M | $0 | $18.95M |
| Total Long-Term Liabilities | $151.39M | $58.85M | $77.91M | $45.41M | $2.18M | $68.83M | $18.95M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $215.6M | $215.8M | $124.5M | $70.98M | $18.81M | $98.11M | $23.24M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $7K | $6K | $5K | $5K | $5K | $1K | $50K |
| Retained Earnings | -$477.21M | -$438.59M | -$365.89M | -$230.54M | -$122.03M | -$48.08M | -$12.2M |
| Comprehensive Income & Other | -$3.83M | -$3.36M | -$2.72M | -$1.75M | -$2.02M | -$1.06M | $0 |
| Other Stockholders' Equity | $710.26M | $661.52M | $545.13M | $501.94M | $469.55M | -$652K | $0 |
| Total Equity | $233.06M | $222.94M | $179.25M | $271.41M | $347.51M | -$48.73M | -$12.15M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $448.66M | $438.73M | $303.75M | $342.39M | $366.33M | $49.38M | $11.09M |
| Supplementary Data | |||||||
| Total Debt | $39.19M | $42.72M | $46.04M | $47M | $0 | $67.76M | $750K |
| Net Debt | -$90.69M | -$181.54M | -$82.06M | -$7.91M | -$346.07M | $26.07M | -$5.25M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$38.63M | -$72.7M | -$135.35M | -$108.5M | -$73.96M | -$35.88M | -$7.74M |
| Depreciation & Amortization | $8.36M | $8.12M | $6.22M | $3.75M | $2.13M | $537K | $72K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $17K | $0 | $0 |
| Stock-Based Compensation | $18.86M | $18.13M | $16.67M | $11.66M | $5.2M | $354K | $0 |
| Changes in Working Capital: | |||||||
| Accounts Receivable | -$7M | $332K | $1.9M | -$187 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $187 | $0 | $0 | $0 |
| Accounts Payable | -$13.71M | $6.25M | $5.76M | -$744K | -$706K | $3.44M | $2.86M |
| Other Working Capital | $11.52M | $84.81M | $64.81M | -$1.39M | $6.99M | $820K | -$1.09M |
| Total Working Capital Change | -$9.19M | $91.4M | $72.47M | -$2.13M | $6.29M | $4.25M | $1.77M |
| Other Non-Cash Items | -$2.2M | -$2.95M | -$3.81M | $2.76M | $960K | $7.68M | -$276K |
| Net Cash from Operating | -$22.8M | $42M | -$43.8M | -$92.47M | -$59.36M | -$23.05M | -$6.17M |
| Investing Activities | |||||||
| Capital Expenditures | -$4.7M | -$3.99M | -$19.04M | -$12.91M | -$9.73M | -$3.39M | -$1.39M |
| Acquisitions | $0 | $0 | $62K | $109K | $79K | $0 | $0 |
| Purchases of Investments | -$376.68M | -$230.36M | -$103.15M | -$384.42M | $0 | $0 | $0 |
| Sales of Investments | $279.54M | $189.9M | $210.93M | $178M | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$101.83M | -$44.45M | $88.8M | -$219.22M | -$9.65M | -$3.39M | -$1.39M |
| Financing Activities | |||||||
| Debt Repaid | - | - | - | - | - | - | -$750K |
| Common Stock Issuance | $30.35M | $944K | $27.49M | $20.05M | $237.75M | $60.06M | $0 |
| Common Stock Repurchases | $0 | -$641K | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | $98.59M | $0 | $411K | -$3.19M | $0 | $0 |
| Net Cash from Financing | $30.35M | $98.89M | $27.49M | $20.47M | $377.56M | $60.06M | $15M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | -$1.16M | $0 |
| Net Change in Cash | -$94.28M | $96.44M | $72.49M | -$291.22M | $308.55M | $32.45M | $7.44M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$22.8M | $42M | -$43.8M | -$92.47M | -$59.36M | -$23.05M | -$6.17M |
| Capital Expenditure | -$4.7M | -$3.99M | -$19.04M | -$12.91M | -$9.73M | -$3.39M | -$1.39M |
| Free Cash Flow | -$27.5M | $38.01M | -$62.84M | -$105.38M | -$69.09M | -$26.44M | -$7.56M |
| Cash at Beginning | $229.12M | $132.68M | $60.19M | $351.41M | $42.86M | $9.24M | $1.8M |
| Cash at End | $134.84M | $229.12M | $132.68M | $60.19M | $351.41M | $41.7M | $9.24M |